Donald Richards

16.0k citations

231 papers · 8.0k indexed · 2 hit papers · h-index 41

Impact in

Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- HER2/EGFR in Cancer Research
Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies

Papers in

Oncology 150
- Colorectal Cancer Treatments and Studies 44
- Cancer Treatment and Pharmacology 38
- Pancreatic and Hepatic Oncology Research 32
- Cancer Immunotherapy and Biomarkers 19
- HER2/EGFR in Cancer Research 19
Cancer Research 41
- Cancer Genomics and Diagnostics 29

Co-authors: Stephen E. Jones Charles S. Fuchs Kristi A. Boehm Edith P. Mitchell Svetislava J. Vukelja John Nemunaitis Allen Lee Cohn Mark Jeffery
Journals: Journal of Clinical Oncology (97 papers)Annals of Oncology (21 papers)Cancer Research (9 papers)Journal of Thoracic Oncology (6 papers)Investigational New Drugs (6 papers)
Partner nations: United States Canada Germany

In The Last Decade

Donald Richards

222 papers receiving 7.8k citations

Hit Papers

align trajectories log scale

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set 2021 · 520 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 Annals of Oncology
2007 Journal of Clinical Oncology

Peers

Countries citing papers authored by Donald Richards

Since Specialization

Citations

This map shows the geographic impact of Donald Richards's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald Richards with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald Richards more than expected).

Fields of papers citing papers by Donald Richards

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald Richards. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald Richards. The network helps show where Donald Richards may publish in the future.

Co-authors

The 25 scholars most cited alongside Donald Richards, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Donald Richards Line = papers co-authored together Donald Richards links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	On the Gaussian product inequality conjecture for disjoint principal minors of Wishart random matrices Electronic Journal of Probability ·Christian Genest, O.M. Agafonov, Donald Richards	2024	2
2	Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium. Journal of Clinical Oncology ·Marta Janezcko, James E. Butrynski, John C. Paschold, Patrick J. Ward, David Waterhouse, Alexander I. Spira, Andrea Monorchio, David Hakimian, Robert M. Jotte, Timothy Larson, Michael W. Meshad, Seiji Sawaki, Donald Richards, Marcus A. Neubauer, Nicholas J. Robert, Margit, 一哲, Robert L. Coleman, David R. Spigel	2024	1
3	A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma European Journal of Cancer ·Thomas Enzler, Anna Nguyen, Jamal Misleh, Alyssa L. Wong, Michael E. Johns, Nathan M. Shumway, Jinqiang Zhao, Robert D. Siegel, Timothy Larson, Wells A. Messersmith, Donald Richards, Jorge Chaves, D. Melini, Mark M. Zalupski, Vaibhav Sahai, Fuat Özbay, Tatyana Buzina, Carles Mengual, نوید ارجمند	2024	2
4	A reflection formula for the Gaussian hypergeometric function of matrix argument Journal of Mathematical Analysis and Applications ·Donald Richards, Purba Sanjaya	2023	1
5	77 JNJ-77242113 treatment induces strong systemic pharmacodynamic response versus placebo in patients with plaque psoriasis: Results from the phase 2, FRONTIER 1 study Journal of Investigative Dermatology ·Andreas Pinter, Kilian Eyerich, Amy S. Paller, Arun Kannan, Yudha Fahmy Ardhyan, Diane Horowitz, Sunita Bhagat, Donald Richards, D Terrace, Bradford L. McRae, Ya‐Wen Yang, Michelle C. Miller, Cynthia Marie Carver DeKlotz, Robert Bissonnette	2023	1
6	43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy Annals of Oncology ·Ticiana Leal, David Berz, Igor I. Rybkin, Wade T. Iams, Débora S. Bruno, Collin M. Blakely, Alexander I. Spira, Manish R. Patel, David Waterhouse, Donald Richards, Anthony Pham, Robert M. Jotte, A. Meunier, David S. Hong, Ronald Shazer, Xiaohong Yan, Aurora de la Vega de Deza, Kai He	2022	13
7	Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study Clinical Cancer Research ·Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael Danso, Lazar Popović, Timothy Pluard, Hyo S. Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald Richards, Sharon Wilks, Dušan Milenković, Jie Xiao, Jessica A. Sorrentino, Janet K. Horton, Joyce O’Shaughnessy	2021	28
8	Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer Journal of Clinical Oncology ·Aditya Bardia, Virginia Kaklamani, Sharon Wilks, Amy Weise, Donald Richards, Wael A. Harb, Cynthia R. Osborne, Robert Wesolowski, Meghan Karuturi, Paul Conkling, Rebecca G. Bagley, Yamei Wang, Maureen G. Conlan, Peter Kabos	2021	67
9	Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma European Journal of Cancer ·Eileen M. O’Reilly, Ignacio García Vargas, Devalingam Mahalingam, Tanios Bekaii‐Saab, Spencer H. Shao, Julie Wolf, L Cupka, Silva Krause, Donald Richards, Kenneth H. Yu, James Roach, Keith T. Flaherty, David P. Ryan	2020	27
10	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer Clinical Cancer Research ·Maura N. Dickler, Cristina Saura, Donald Richards, Ian E. Krop, Andrés Cervantes, Philippe L. Bédard, Manish R. Patel, Lajos Pusztai, Mafalda Oliveira, G. Da Molin, Na Cui, Timothy R. Wilson, Thomas J. Stout, Michael C. Wei, Jerry Y. Hsu, José Baselga	2018	57
11	Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy Annals of Oncology ·Kenneth Nealson H., Alexander I. Spira, Collin M. Blakely, Kai He, David Berz, Donald Richards, Andrea Resciniti, Abigail L. Savage, N'Guyen Sylvain, Erminia Massarelli, Robert M. Jotte, S Wang, James G. Christensen, Peter Olson, Vanessa Tassell, Leora Horn	2018	9
12	Whole blood FPR1 mRNA expression predicts both non‐small cell and small cell lung cancer International Journal of Cancer ·Scott Morris, Anil Vachani, Harvey I. Pass, William N. Rom, Mazen I. Negm, Glen J. Weiss, D. Kyle Hogarth, George C. Runger, Donald Richards, Troy Shelton, David Mallery	2018	14
13	Distance correlation coefficients for Lancaster distributions Journal of Multivariate Analysis ·W. L. Crofford, Dominic Edelmann, Donald Richards	2016	8
14	A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer Clinical Cancer Research ·Alex A. Adjei, Donald Richards, Anthony B. El-Khoueiry, Fadi Braiteh, Vanesia Amelia Sebayang, Joe Stephenson, Aram F. Hezel, Morris Sherman, Lawrence Garbo, 刘曦子, Cory Iverson, Jeffrey N. Miner, Zancong Shen, Li‐Tain Yeh, Mingxia Gui, David M. Wilson, Kimberly J. Manhard, Prabhu Rajagopalan, Heiko Krissel, Neil J. Clendeninn	2015	16
15	Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study Annals of Oncology ·Eric Van Cutsem, C. Boni, Josep Tabernero, Bartomeu Massutí, Gary Middleton, Faysal Dane, Peter Reichardt, Francisco Pimentel, Allen Lee Cohn, Philippe Follana, Michael Clemens, Alberto Zaniboni, Vladimir Moiseyenko, Mark Harrison, Donald Richards, Hans Prenen, Simon Pernot, Osamu Toyota, Simon Hitier, P. Rougier	2014	88
16	Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology Annals of Oncology ·Shadia I. Jalal, 洋三中村, A. Melnyk, Donald Richards, A.M. Prokhorov, M. Neubauer, Rafat Ansari, Ramaswamy Govindan, Daniel Bruetman, William B. Fisher, T. Breen, Cynthia S. Johnson, Menggang Yu, Lawrence H. Einhorn, Nasser H. Hanna	2011	58
17	Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735 Journal of Clinical Oncology ·Stephen E. Jones, Frankie A. Holmes, Joyce O’Shaughnessy, Joanne L. Blum, Svetislava J. Vukelja, Kristi McIntyre, John Pippen, Loh Tze Liang, Robert Kirby, John F. Sandbach, William Hyman, Donald Richards, Robert Mennel, Kristi A. Boehm, Wally Meyer, Lina Asmar, Daniel Mackey, Stefan Riedel, Hyman B. Muss, Michael A. Savin	2009	400
18	Randomized Double-Blind Phase II Trial Comparing Gemcitabine Plus LY293111 Versus Gemcitabine Plus Placebo in Advanced Adenocarcinoma of the Pancreas The Cancer Journal ·Muhammad Wasif Saif, Helmut Oettle, Walter L. Vervenne, James P. Thomas, Gary Spitzer, Carla Visseren‐Grul, Nathan Enas, Donald Richards	2009	44
19	P2-292: A randomized Phase 3 trial of gemcitabine with or without carboplatin in performance status 2 (PS2) patients with advanced (stage IIIB with pleural effusion or IV) non-small-cell lung cancer (NSCLC) Journal of Thoracic Oncology ·Craig H. Reynolds, Paul Conkling, Donald Richards, James F. Fitzgibbons, James C. Arseneau, Kristi A. Boehm, Lina Asmar, Jane Bromund, Guangbin Peng, Coleman K. Obasaju	2007	3
20	Experimental Approaches to Kuttner's Problem Experimental Mathematics ·Tilmann Gneiting, Kjell Kanis, Donald Richards	2001	4

About Donald Richards

Donald Richards is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Statistics and Probability and Genetics, having authored 231 papers that have together received 8.0k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (44 papers), Lung Cancer Treatments and Mutations (40 papers), Cancer Treatment and Pharmacology (38 papers), Pancreatic and Hepatic Oncology Research (32 papers), Cancer Genomics and Diagnostics (29 papers), Advanced Breast Cancer Therapies (20 papers), Cancer Immunotherapy and Biomarkers (19 papers) and HER2/EGFR in Cancer Research (19 papers). The work is most often cited by research in Oncology (5.2k citations), Cancer Research (2.1k citations), Pulmonary and Respiratory Medicine (2.6k citations), Hepatology (454 citations) and Pathology and Forensic Medicine (685 citations). Donald Richards has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Stephen E. Jones, Charles S. Fuchs, Kristi A. Boehm, Edith P. Mitchell, Svetislava J. Vukelja, John Nemunaitis, Allen Lee Cohn, Mark Jeffery, Vinod Ganju and Robert Mennel. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Journal of Thoracic Oncology and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact